Pulmonary Arterial Hypertension Therapeutics Market Size (7MM) is expected to grow at a significant CAGR of 6.7% During the forecast period of 2026-2036 | DelveInsight

DelveInsight's "Pulmonary Arterial Hypertension Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Pulmonary Arterial Hypertension Treatment Market Report @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Pulmonary Arterial Hypertension Market Report
• In February 2026, Gossamer Bio announced topline Phase III results for Seralutinib, an investigational inhaled therapy for adults with PAH.
• In 2025, the US accounted for the highest Pulmonary Arterial Hypertension Diagnosed Prevalent Cases, with approximately 40,000 cases, which are expected to increase by 2036.
• Idiopathic/heritable PAH had the highest number of subtype-specific cases in the US in 2025 with nearly 19,000 cases, which is predicted to rise by 2036.
• In 2025, the Germany reported the highest number of diagnosed prevalent cases of PAH among EU4 and the UK, with approximately 7,000 cases.
• In 2025, Japan reported nearly 19,000 diagnosed prevalent cases of PAH in females and nearly 5,000 cases in males, with numbers projected to rise by 2036.
• The leading Pulmonary Arterial Hypertension Companies include Merck, Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharm, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Sumitomo Pharma (Enzyvant Therapeutics), Cereno Scientific, AstraZeneca, and others.
• Promising Pulmonary Arterial Hypertension Therapies such as Ralinepag, RT234 (vardenafil inhalation powder), Seralutinib (GB002), YUTREPIA (inhaled dry powder formulation of treprostinil), L606 (liposomal treprostinil), Treprostinil Palmitil, CS1, ROC-101, IKT-001, and others.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Arterial Hypertension Epidemiology Segmentation in the 7MM
• Total Pulmonary Arterial Hypertension Prevalent Cases
• Total Pulmonary Arterial Hypertension Diagnosed Prevalent Cases
• Pulmonary Arterial Hypertension Age-specific Cases
• Pulmonary Arterial Hypertension Class-specific Cases
• Pulmonary Arterial Hypertension Gender-specific Cases
• Pulmonary Arterial Hypertension Subtype-specific Cases
• Total Pulmonary Arterial Hypertension Treated Cases

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Arterial Hypertension Approved Therapies
• Inhaled treprostinil (YUTREPIA): Liquidia Technologies
Treprostinil (YUTREPIA), developed by Liquidia Technologies, is an inhaled dry powder formulation of treprostinil delivered through a convenient, palm-sized device designed using Liquidia's PRINT technology to enhance deep-lung delivery to treat PAH.

Pulmonary Arterial Hypertension Pipeline Analysis
• Ralinepag: United Therapeutics
Ralinepag is a novel, oral, selective, and potent prostacyclin receptor agonist being developed by United Therapeutics for the treatment of PAH. In vitro studies indicate that ralinepag has high binding affinity and selectivity at the human prostacyclin (IP) receptor. In phase II studies, ralinepag demonstrated a potential for a once-a-day dosing profile and potentially enhanced affinity compared to selexipag.

Pulmonary Arterial Hypertension Companies
Merck, Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharm, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Sumitomo Pharma (Enzyvant Therapeutics), Cereno Scientific, AstraZeneca, and others.

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Arterial Hypertension Market Outlook
Current therapies primarily work by dilating pulmonary blood vessels to reduce resistance and improve heart function, with treatment strategies guided by risk assessment based on clinical, functional, and hemodynamic parameters to achieve a low-risk status and improve outcomes such as survival, quality of life, and symptom control. The main drug classes used include PDE5 inhibitors, sGC stimulators, endothelin receptor antagonists, and prostacyclin analogs/agonists, which target the nitric oxide, endothelin, and prostacyclin pathways.

Scope of the Pulmonary Arterial Hypertension Market Report
• Study Period: 2022-2036
• Coverage: 7MM
• Pulmonary Arterial Hypertension Companies- Merck, Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharm, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Sumitomo Pharma (Enzyvant Therapeutics), Cereno Scientific, AstraZeneca, and others.
• Pulmonary Arterial Hypertension Therapies- Ralinepag, RT234 (vardenafil inhalation powder), Seralutinib (GB002), YUTREPIA (inhaled dry powder formulation of treprostinil), L606 (liposomal treprostinil), Treprostinil Palmitil, CS1, ROC-101, IKT-001, and others.
• Pulmonary Arterial Hypertension Therapeutic Assessment- Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Arterial Hypertension Unmet Needs, KOL's views, Analyst's views, Pulmonary Arterial Hypertension Market Access and Reimbursement

To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Pulmonary Arterial Hypertension Market Report Introduction
2. Executive Summary for Pulmonary Arterial Hypertension
3. SWOT analysis of Pulmonary Arterial Hypertension
4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance
5. Pulmonary Arterial Hypertension Market Overview at a Glance
6. Pulmonary Arterial Hypertension Disease Background and Overview
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Arterial Hypertension
9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices
10. Pulmonary Arterial Hypertension Unmet Needs
11. Pulmonary Arterial Hypertension Emerging Therapies
12. Pulmonary Arterial Hypertension Market Outlook
13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2020-2034)
14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies
15. Pulmonary Arterial Hypertension Market Drivers
16. Pulmonary Arterial Hypertension Market Barriers
17. Pulmonary Arterial Hypertension Appendix
18. Pulmonary Arterial Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.